BioLineRx Ltd.
BLRX
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarciā¦ read more
Healthcare
Biotechnology
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.27
Price-1.80%
-$0.06
1Y
Price
Market Cap
$13.939m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1147.4%
EBITDA Margin-1296.0%
Net Profit Margin-58.2%
Free Cash Flow MarginRevenue
$17.251m
-40.4%
1y CAGR+154.2%
3y CAGR+115.6%
5y CAGREarnings
-$7.822m
+15.2%
1y CAGR-14.3%
3y CAGR-8.8%
5y CAGREPS
-$1.05
-775.0%
1y CAGR-261.2%
3y CAGR-190.6%
5y CAGRBook Value
$20.072m
$43.267m
Assets$23.195m
Liabilities$12.603m
DebtDebt to Assets
29.1%
6.4x
Debt to EBITDAFree Cash Flow
-$21.198m
+51.7%
1y CAGR-8.8%
3y CAGR-9.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company